Drug Profile
Research programme: malononitrilamide compounds - Sanofi-Aventis/Astellas Pharma
Alternative Names: Malononitrilamide compounds research programme - Sanofi-Aventis/FujisawaLatest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Nitriles
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 30 Jun 2006 Discontinued - Preclinical for Transplant rejection in Europe (unspecified route)
- 30 Jun 2006 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma